论文部分内容阅读
目的 通过观察高血压病患者血清Ⅲ型前胶原（ＰＣⅢ）、层粘连蛋白（ＬＮ）、透明质酸（ＨＡ）含量的变化，以及苯那普利对其影响，探讨上述参数作为心肌肥厚指标的临床价值。评价苯那普利对高血压性心肌纤维化的影响。方法测定６４例高血压病患者在用苯那普利前后血清中ＰＣⅢ、ＬＮ、ＨＡ水平的变化，并将左室心肌重指数（ＬＶＭＩ）与上述各参数作相关分析。结果 高血压伴左室肥厚组较高血压不伴左室肥厚组及正常对照组的血清ＰＣⅢ、ＬＮ、ＨＡ含量显著增高，用苯那普利后伴与不伴左室肥厚的高血压患者上述指标均明显下降；血清ＰＣⅢ、ＬＮ、ＨＡ均与ＬＶＭＩ呈显著正相关。结论 血清ＰＣⅢ、ＬＡ、ＨＡ均可作为高血压左室肥厚患者组织纤维化的血清学指标，苯那普利可防治高血压患者心肌纤维化的发生。
Objective To observe the changes of serum levels of type Ⅲ procollagen (PC Ⅲ), laminin (LN) and hyaluronic acid (HA) in patients with essential hypertension and the effects of benazepril on the above parameters as indexes of cardiac hypertrophy Clinical Value. To evaluate the effects of benazepril on hypertensive myocardial fibrosis. Methods The levels of PCⅢ, LN and HA in serum of 64 hypertensive patients before and after benazepril were measured, and the correlation between left ventricular myocardial index (LVMI) and the above parameters was analyzed. Results The levels of PCⅢ, LN and HA in hypertensive patients with left ventricular hypertrophy and left ventricular hypertrophy were significantly higher than those in hypertensive patients without hypertension and left ventricular hypertrophy Indicators were significantly decreased; serum PC Ⅲ, LN, HA were significantly positively correlated with LVMI. Conclusions Serum PCⅢ, LA and HA can be used as serological markers of tissue fibrosis in hypertensive patients with left ventricular hypertrophy. Benazepril may prevent myocardial fibrosis in hypertensive patients.